Probucol up-regulates paraoxonase 1 expression in hepatocytes of hypercholesterolemic rabbits

Journal of Cardiovascular Pharmacology

Volumn 47, Issue 1, 2006, Pages 77-81

  Hong, Shao Cai ^a   Zhao, Shui Ping ^a   Wu, Zhi Hong ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Antioxidant; High density lipoprotein; Paraoxonase 1; Probucol

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; CHOLESTEROL; GELATINASE A; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; MESSENGER RNA; PROBUCOL; STARCH; SUPEROXIDE DISMUTASE; ANTIOXIDANT; ARYLDIALKYLPHOSPHATASE; HYPOCHOLESTEROLEMIC AGENT; LIPID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROSCLEROSIS; CELL ISOLATION; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL DIET; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; HYPERCHOLESTEROLEMIA; LIVER CELL; LIVER PERFUSION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESTENOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; ANIMAL; BLOOD; BODY WEIGHT; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; RABBIT;

ANIMALS; ANTICHOLESTEREMIC AGENTS; ANTIOXIDANTS; ARYLDIALKYLPHOSPHATASE; BODY WEIGHT; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HEPATOCYTES; HYPERCHOLESTEROLEMIA; LIPIDS; MALE; MALONDIALDEHYDE; PROBUCOL; RABBITS; RNA, MESSENGER; SUPEROXIDE DISMUTASE;

EID: 33646712327     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fjc.0000194687.19335.59     Document Type: Article

References (41)

1. Navab M, Hama SY, Hough GP, et al. High-density associated enzymes: their role in vascular biology. Curr Opin Lipidol. 1998;9:449-456.
2. Mackness B, Durrington PN, Mackness MI. The paraoxonase gene family and coronary heart disease. Curr Opin Lipidol. 2002;13:357-362.
3. Aviram M, Rosenblat M, Bisgaier CL, et al. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest. 1998;101:1581-1590.
4. Shih DM, Gu L, Xia YR, et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature. 1998;394:284-287.
5. Ng CJ, Shih DM, Hama SY, et al. The paraoxonase gene family and atherosclerosis. Free Radic Biol Med. 2005;38:153-163.
6. Mackness M, Bouiller A, Hennuyer N, et al. Paraoxonase activity is reduced by a pro-atherosclerotic diet in rabbits. Biochem Biophys Res Commun. 2000;269:232-236.
7. Mackness MI, Mackness B, Durrington PN. Paraoxonase and coronary heart disease. Atheroscler Suppl. 2002;3:49-55.
8. Mackness MI, Durrington B, Mackness B. How HDL protects against the effects of lipid peroxidation. Curr Opin Lipidol. 2000;11:383-388.
9. Mackness MI, Durrington PN, Mackness B. The role of paraoxonase 1 activity in cardiovascular disease: potential for therapeutic intervention. Am J Cardiovasc Drug. 2004;4:211-217.
10. Mackness MI, Durrington PN, Mackness B. Paraoxonase 1 activity, concentration and genotype in cardiovascular disease. Curr Opin Lipidol. 2004;15:399-404.
11. Tardif JC, Gregoire J, Schwartz L, et al. Canadian Antioxidation Restenosis Trial (CART) Investigators. Effects of AGI-1067 and probucol after percutaneous coronary interventions-Canadian Antioxidant Restenosis Trial (CART). Circulation. 2003;107:552-558.
12. Wakeyama T, Ogawa H, Iida H, et al. Effects of candesartan and probucol on restenosis after coronary stenting - Results of Insight of Stent Intimal Hyperplasia Inhibition by New Angiotension II Receptor Antagonist (ISHIN) Trial. Circ J. 2003;67:519-524.
13. Sawayama Y, Shimizu C, Maeda N, et al. Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia: Fukuoka Atherosclerosis Trial (FAST). J Am Coll Cardiol. 2002;39:610-616.
14. Mackness B, Durrington PN, Mackness MI. Lack of protection against oxidative modification of LDL by avian HDL. Biochem Biophys Res Commun. 1998;247:443-446.
15. Buckley MM, Goa KL, Price AH, et al. Probucol. A reappraisal of its pharmacological properties and therapeutic use in hypercholesterolaemia. Drugs. 1989;37:761-800.
16. Tardif JC, Gregoire J, L'Allier PL. Prevention of restenosis with antioxidants: mechanisms and implications. Am J Cardiovasc Drugs. 2002;2:323-334.
17. Tardif JC. Antioxidants and atherosclerosis: emerging drug therapies. Curr Atheroscler Rep. 2005;7:71-77.
18. Sasahara M, Raines EW, Chait A, et al. Inhibition of hypercholesterolemia-induced atherosclerosis in the nonhuman primate by probucol. 1. Is the extent of atherosclerosis related to resistance of LDL to oxidation? J Clin Invest. 1994;94:155-164.
19. Nagano Y, Nakamura T, Matsuzawa Y, et al. Probucol and atherosclerosis in the Watanabe heritable hyperlipidemic rabbit - long-term antiatherogenic effect and effects on established plaques. Atherosclerosis. 1992;92:131-140.
20. Noto H, Kawamura M, Hashimoto Y, et al. Modulation of HDL metabolism by probucol in complete cholesteryl ester transfer protein deficiency. Atherosclerosis. 2003;171:131-136.
21. Abbott CA, Mackness MI, Kumar S, et al. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler Thromb Vasc Biol. 1995;15:1812-1818.
22. Seglen PO. Preparation of isolated rat liver cells. Methods Cell Biol. 1976;13:29-83.
23. Djahansouzi S, Braesen JH, Koenig K, et al. The effect of pharmacological doses of different antioxidants on oxidation parameters and atherosclerosis in hyperlipidaemic rabbits. Atherosclerosis. 2001;154:387-398.
24. Mantha SV, Kalra J, Prasad K. Effects of probucol on hypercholesterolemia-induced changes in antioxidant enzymes. Life Sci. 1996;58:503-509.
25. Tsujita M, Yokoyama S. Selective inhibition of free apolipoprotein- mediated cellular lipid efflux by probucol. Biochemistry. 1996;35:13011-13020.
26. Francois M, Kojda G. Effect of hypercholesterolemia and oxidative stress on the nitric oxide-cGMP pathway. Neurochem Int. 2004;45:955-961.
27. Devasagayam TP, Tilak JC, Boloor KK, et al. Free radicals and antioxidants in human health: current status and future prospects. J Assoc Phys India. 2004;52:794-804.
28. Hayek T, Fuhrman B, Vaya J, et al. Reduced progression of atherosclerosis in apolipoprotein E-deficient mice following consumption of red wine, or its polyphenols quercetin or catechin, is associated with reduced susceptibility of LDL to oxidation and aggregation. Arterioscler Thromb Vasc Biol. 1997;17:2744-2752.
29. Traverso N, Menini S, Maineri EP, et al. Malondialdehyde, a lipoperoxidation-derived aldehyde, can bring about secondary oxidative damage to proteins. J Gerontol A Biol Sci Med Sci. 2004;59:B890-B895.
30. Memisogulari R, Bakan E. Levels of ceruloplasmin, transferring, and lipid peroxidation in serum of patients with Type 2 diabetes mellitus. J Diabetes Complications. 2004;18:193-197.
31. Maytin M, Leopold J, Loscalzo J. Oxidant stress in vasculature. Curr Atheroscler Rep. 1999;1:156-164.
32. Wu A, Hinds CJ, Thiemermann C. High-density lipoproteins in sepsis and septic shock: metabolism, actions, and therapeutic applications. Shock. 2004;21:210-221.
33. Karakucuk S, Baskol G, Oner AO, et al. Serum paraoxonase activity is decreased in the active stage of Behcxet's disease. Br J Ophthalmol. 2004;88:1256-1258.
34. Serhatlioglu S, Gursu MF, Gulcu F, et al. Levels of paraoxonase and arylesterase activities and malondialdehyde in workers exposed to ionizing radiation. Cell Biochem Funct. 2003;21:371-375.
35. Diaz MN, Frei B, Vita JA, et al. Anti-oxidants and atherosclerotic heart disease. N Engl J Med. 1997;337:408-416.
36. Navab M, Anantharamaiah GM, Reddy ST, et al. Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice. Circulation. 2004;109:3215-3220.
37. Deakin S, Leviev I, Guernier S, et al. Simvastatin modulates expression of the PON1 gene and increases serum paraoxonase: a role for sterol regulatory element-binding protein-2. Arterioscler Thromb Vasc Biol. 2003;23:2083-2089.
38. Ota K, Suehiro T, Arii K, et al. Effect of pitavastatin on transactivation of human serum paraoxonase 1 gene. Metabolism. 2005;54:142-150.
39. Kabaroglu C, Mutaf I, Boydak B, et al. Association between serum paraoxonase activity and oxidative stress in acute coronary syndromes. Acta Cardiol. 2004;59:6050-6061.
40. Kirschbaum B. Correlation studies of plasma paraoxonase activity and uric acid concentration with AAPH-induced erythrocyte hemolysis in hemodialysis patients. Artif Organs. 2004;28:259-264.
41. Ishigami M, Yamashita S, Sakai N, et al. High-density lipoproteins from probucol-treated patients have increased capacity to promoted cholesterol efflux from mouse peritoneal macrophages loaded with acetylated low density lipoproteins. Eur J Clin Invest. 1997;27:285-292.